RESUMEN
Background: People living with HIV (PLWH) are at increased risk of severe COVID-19. The UK recommends vaccination against COVID-19 for PLWH with two primary doses, a booster dose, then seasonal boosters (i.e. four doses by Autumn 2022). Vaccination uptake in the UK has been lower among non-white minority ethnic groups than in the white British population, despite these groups having a higher risk of severe COVID-19. Method(s): We evaluated vaccine uptake by PLWH attending treatment services at two NHS Trusts in North East England. To ensure representation of minorities, alternating PLWH from white and ethnic minorities (excluding white minorities) were purposively selected for review from the HIV and AIDS Reporting System;vaccination data were obtained from regional integrated care records. Result(s): 200 PLWH were included. 103 (51.5%) were from ethnic minority groups, of whom 78 (75.7%) were of black African ethnicity. Vaccination rates in the total population and among ethnic groups are shown in the table below. Similar proportions of white and minority ethnic background PLWH had received up to two vaccinations. These proportions among white PLWH were similar to those reported in the general English population, while fewer Black African PLWH were unvaccinated than in the general population (14.1% vs. 26%, data not shown). Vaccine uptake among PLWH diverged beyond 3 doses, with white people being almost three times as likely to have received four doses (OR 2.92;95% CI 1.63 to 5.19;pvalue for difference in distribution across all doses=0.005). Conclusion(s): Although ethnic minority PLWH were less likely to be fully vaccinated than white ethnicity PLWH, the proportion of unvaccinated black African PLWH was lower than that reported from the general population. This could infer that regular contact with healthcare professionals coupled with consistent promotion of vaccination by HIV clinicians can improve uptake. (Table Presented).
RESUMEN
Background: People living with HIV (PLWH) are at increased risk of severe or critical COVID-19. This is in addition to the increased risk associated with any coexisting conditions such as chronic pulmonary disease (CPD), chronic kidney disease and cardiovascular disease. Vaccination against COVID-19 is therefore strongly recommended for PLWH. Method(s): We conducted a descriptive study to evaluate comorbidities among PLWH attending for HIV care at two NHS Trusts in North East England and who were under- or unvaccinated against COVID-19, defined as having received either zero or 1 doses of any COVID-19 vaccine by 01/10/2022. PLWH under active care were identified using the HIV and AIDS Reporting System (HARS) dataset. Vaccination data were obtained from regional integrated care records (RICR) and cross-referenced with HARS. Information on comorbidities was collated for any patients who were under- or unvaccinated. To quantify risk and clinical vulnerability, we calculated the Charlson Comorbidity Index (CCI) for each of these patients. A CCI score >=1 is associated with mortality/poor outcomes in patients with COVID-19. Result(s): 141 under- or unvaccinated patients were identified out of a total cohort of 1492 patients who attended for HIV care (9.5%);of these, 96 (68.1%) and 45 (31.9%) had received zero and one vaccination respectively. The median age of this under-/unvaccinated cohort was 41 years and 91 (64.5%) were male. 62 patients (44.0%) had a CCI score of 1 or more;13 patients (9.2%) had a diagnosis of AIDS during the time period evaluated;11 (84.6%) of the patients with an AIDS diagnosis were completely unvaccinated. Non-HIV comorbidities included liver disease (10/141, 7.1%), solid organ cancer (5/141, 3.5%), CPD (4/141, 2.8%) and connective tissue disease (3/141, 2.1%). Six patients (4.3%) had >=2 comorbidities. Conclusion(s): Nearly half of the under-/unvaccinated PLWH attending our services were identified as being at an increased risk of having a poor outcome in the event of contracting COVID-19. Proactively identifying these individuals would allow services to offer tailored support in making informed decisions about vaccinations. Useful strategies may include the use of patient information leaflets and targeted discussion with patients explaining their individual risk from COVID-19.
RESUMEN
Introduction: During the 2021/22 influenza season, media outlets reported on potential influenza A/B and CoVid-19 coinfection, termed 'flu-rona'. National guidelines (Management of CAP in Adults, BTS, 2009) suggest patients admitted with respiratory infection should undergo respiratory viral PCR (rvPCR) swabbing, severity dependent. We assessed: (1) UK teaching hospital seasonal rvPCR swab data for flu-rona (2) rvPCR swabbing behaviour in respiratory inpatients. Method(s): (1) Collect data on all rvPCR swabs [Panther Analyser] from 1/12/21 for 6 weeks with indication & CoVid swab result within 7 days of rvPCR. (2) Assess rvPCR swabbing in respiratory ward admissions from 1/1/22 for 4 weeks. Result(s): (1) 234 patients underwent rvPCR testing, with none positive for influenza A/B. n=23 were positive for any virus. Haematology-oncology swabbed 136 patients (as per protocol). Of the remainder (n=98), 22.4% (n=22) had respiratory symptoms (RSx) - with one positive rvPCR swab. 10/98 were CoVid positive on concurrent testing, of whom 7 had RSx. (2) 117 patients were admitted to the respiratory ward, of whom 73 had RSx;of these n=53 CoVid positive with only 1 (2%) undergoing rvPCR swab, and 20 CoVid negative with only 2 (10%) undergoing rvPCR swabs (see table) Conclusion(s): We found no flu-rona and low rates of rvPCR swabbing in those with RSx despite national guidelines. While these data suggest rates of flu-rona are likely low, they highlight dangers of diagnostic blindness in the age of CoVid-19 and possible nihilistic beliefs regarding rvPCR testing in general.